1374640-70-6 | Co-1686

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$9.00	$6.00
5mg	98%	in stock	$13.00	$9.00
10mg	98%	in stock	$18.00	$12.00
50mg	98%	in stock	$58.00	$40.00
100mg	98%	in stock	$85.00	$59.00
250mg	98%	in stock	$138.00	$96.00
1g	98%	in stock	$329.00	$230.00

Description

• Catalog Number: AB52193
• Chemical Name: Co-1686
• CAS Number: 1374640-70-6
• Molecular Formula: C27H28F3N7O3
• Molecular Weight: 555.5515
• MDL Number: MFCD26793864
• SMILES: C=CC(=O)Nc1cccc(c1)Nc1nc(ncc1C(F)(F)F)Nc1ccc(cc1OC)N1CCN(CC1)C(=O)C

Computed Properties

• Complexity: 871
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 40
• Hydrogen Bond Acceptor Count: 11
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 8
• XLogP3: 4

Literature

• Osimertinib induces autophagy and apoptosis via reactive oxygen species generation in non-small cell lung cancer cells.

  Toxicology and applied pharmacology 20170415

• Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers.

  Journal of medicinal chemistry 20160728

• Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer.

  Journal of hematology & oncology 20160101

• Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.

  The Lancet. Oncology 20150901

• Dacomitinib in lung cancer: a 'lost generation' EGFR tyrosine-kinase inhibitor from a bygone era?

  Drug design, development and therapy 20150101

• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  Cancer discovery 20131201

• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

  Journal of the National Comprehensive Cancer Network : JNCCN 20130201